Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunityChristian S Hinrichs, Zachary A Borman, Lydie Cassard, et al.International Journal of Cancer|September 19, 2008
Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular responseLydie Cassard, Joel F G Cohen-Solal, Emilie M Fournier, et al.Science Advances|November 8, 2023
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLCMarie Naigeon, Matthieu Roulleaux Dugage, François-Xavier Danlos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.Nature Communications|May 3, 2020
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancerClélia Coutzac, Jean-Mehdi Jouniaux, Angelo Paci, et al.Journal for Immunotherapy of Cancer|May 31, 2022
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 studyLucia Carril-Ajuria, Aude Desnoyer, Maxime Meylan, et al.Nature|April 29, 2026
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1Lambros Tselikas, Sandrine Susini, Matthieu Texier, et al.Blood|May 20, 2009
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenLaura A Johnson, Richard A Morgan, Mark E Dudley, et al.European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.Journal of Experimental & Clinical Cancer Research : CR|July 6, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Francois-Xavier Danlos, Andreea Varga, et al.Pageof 5